The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy
- PMID: 21351303
- PMCID: PMC4094092
- DOI: 10.1002/pds.2049
The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy
Abstract
Purpose: Anti-tumor necrosis factor-alpha (anti-TNF) therapies are associated with severe mycobacterial infections in rheumatoid arthritis patients. We developed and validated electronic record search algorithms for these serious infections.
Methods: The study used electronic clinical, microbiologic, and pharmacy records from Kaiser Permanente Northern California (KPNC) and the Portland Veterans Affairs Medical Center (PVAMC). We identified suspect tuberculosis and nontuberculous mycobacteria (NTM) cases using inpatient and outpatient diagnostic codes, culture results, and anti-tuberculous medication dispensing. We manually reviewed records to validate our case-finding algorithms.
Results: We identified 64 tuberculosis and 367 NTM potential cases, respectively. For tuberculosis, diagnostic code positive predictive value (PPV) was 54% at KPNC and 9% at PVAMC. Adding medication dispensings improved these to 87% and 46%, respectively. Positive tuberculosis cultures had a PPV of 100% with sensitivities of 79% (KPNC) and 55% (PVAMC). For NTM, the PPV of diagnostic codes was 91% (KPNC) and 76% (PVAMC). At KPNC, ≥ 1 positive NTM culture was sensitive (100%) and specific (PPV, 74%) if non-pathogenic species were excluded; at PVAMC, ≥1 positive NTM culture identified 76% of cases with PPV of 41%. Application of the American Thoracic Society NTM microbiology criteria yielded the highest PPV (100% KPNC, 78% PVAMC).
Conclusions: The sensitivity and predictive value of electronic microbiologic data for tuberculosis and NTM infections is generally high, but varies with different facilities or models of care. Unlike NTM, tuberculosis diagnostic codes have poor PPV, and in the absence of laboratory data, should be combined with anti-tuberculous therapy dispensings for pharmacoepidemiologic research.
Copyright © 2010 John Wiley & Sons, Ltd.
Conflict of interest statement
Similar articles
-
Mycobacterial diseases and antitumour necrosis factor therapy in USA.Ann Rheum Dis. 2013 Jan;72(1):37-42. doi: 10.1136/annrheumdis-2011-200690. Epub 2012 Apr 20. Ann Rheum Dis. 2013. PMID: 22523429
-
Increased risk of mycobacterial infections associated with anti-rheumatic medications.Thorax. 2015 Jul;70(7):677-82. doi: 10.1136/thoraxjnl-2014-206470. Epub 2015 Apr 24. Thorax. 2015. PMID: 25911222
-
Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.Eur Respir J. 2014 Nov;44(5):1289-95. doi: 10.1183/09031936.00063514. Epub 2014 Aug 7. Eur Respir J. 2014. PMID: 25102962
-
A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.Vaccine. 2013 Dec 30;31 Suppl 10:K41-61. doi: 10.1016/j.vaccine.2013.03.075. Vaccine. 2013. PMID: 24331074 Review.
-
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.Emerg Infect Dis. 2009 Oct;15(10):1556-61. doi: 10.3201/eid1510.090310. Emerg Infect Dis. 2009. PMID: 19861045 Free PMC article. Review.
Cited by
-
Nontuberculous mycobacterial pulmonary disease (NTM PD) incidence trends in the United States, 2010-2019.BMC Infect Dis. 2024 Oct 2;24(1):1094. doi: 10.1186/s12879-024-09965-y. BMC Infect Dis. 2024. PMID: 39358723 Free PMC article.
-
Reductions in hospitalisations and emergency department visits with early antibiotic initiation in nontuberculous mycobacterial lung disease.ERJ Open Res. 2024 Jul 22;10(4):00963-2023. doi: 10.1183/23120541.00963-2023. eCollection 2024 Jul. ERJ Open Res. 2024. PMID: 39040577 Free PMC article.
-
Geographic Variation and Environmental Predictors of Nontuberculous Mycobacteria in Laboratory Surveillance, Virginia, USA, 2021-20231.Emerg Infect Dis. 2024 Mar;30(3):548-554. doi: 10.3201/eid3003.231162. Emerg Infect Dis. 2024. PMID: 38407146 Free PMC article.
-
Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.Chest. 2024 May;165(5):1058-1069. doi: 10.1016/j.chest.2023.12.006. Epub 2023 Dec 10. Chest. 2024. PMID: 38086472
-
Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review.Clin Chest Med. 2023 Dec;44(4):675-721. doi: 10.1016/j.ccm.2023.08.012. Epub 2023 Sep 21. Clin Chest Med. 2023. PMID: 37890910 Review.
References
-
- Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269–281. - PubMed
-
- Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69:i2–i29. - PubMed
-
- Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol. 2005;23:S168–S171. - PubMed
-
- Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–155. - PubMed
-
- Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl 3):S199–S203. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
